Business UpdateApr 22, 2026, 08:03 AM
Arcutis' ZORYVE Gets Strong AAD Recommendation for Pediatric Atopic Dermatitis
AI Summary
Arcutis Biotherapeutics announced that its ZORYVE® (roflumilast) cream received a strong recommendation in the American Academy of Dermatology (AAD) clinical practice guidelines for pediatric atopic dermatitis. The guidelines recommend ZORYVE cream for children aged 2-5 years and 6 years and older, citing its proven efficacy, safety, and tolerability as a steroid-free topical PDE4 inhibitor. This endorsement reinforces ZORYVE's value for long-term use in managing this chronic condition affecting approximately 9.6 million U.S. children.
Key Highlights
- ZORYVE cream received a strong recommendation in AAD pediatric guidelines.
- Recommended for children aged 2-5 years (0.05%) and 6+ years (0.15%).
- Recognized for high efficacy, safety, and tolerability in pediatric patients.
- ZORYVE is a steroid-free topical PDE4 inhibitor.
- Atopic dermatitis affects approximately 9.6 million children in the U.S.
Price Impact
More from ARQT